sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) combine with ozagrel sodium in the treatment of acute cerebral infarction

Date : 2016/9/29 10:52:16

Jiangsu Province, Xinyi Railway Hospital researchers published papers to observe the combination of ozagrel sodium and vinpocetine(CAS 42971-09-5) in the treatment of acute cerebral infarction clinical efficacy and safety. Studies have shown that Ozagrel sodium combined with vinpocetine treatment of acute cerebral infarction efficacy, no adverse reactions, is worthy of clinical application. The article published on 2014 seventh issue of "Journal of Practical Clinical Medicine".

Eighty patients with acute cerebral infarction were randomly divided into two groups: treatment group Ozagrel sodium combined with vinpocetine(CAS 42971-09-5) intravenous infusion, 1 / d, 2 groups were 10 d treatment.

The total effective rate of the treatment group was 92.5% (37/40), which was significantly better than that of the control group (75.0%, 30/40) (P <0.01). The neurological deficit scores of the two groups were better than those of the control group (P <0.01). 2 groups were no significant adverse reactions.